A novel prognostic model based on CA stage for enhanced stratification and survival prediction in patients with Natural killer/T-cell lymphoma

基于CA分期的新型预后模型,用于增强自然杀伤/T细胞淋巴瘤患者的分层和生存预测

阅读:1

Abstract

This study aimed to identify key prognostic factors for Natural killer/T-cell lymphoma (NKTCL) in the context of L-asparaginase/pegaspargase-based therapy and to develop a simplified yet accurate prognostic model for risk stratification. Data from 854 NKTCL patients at the Sun Yat-sen University Cancer Center were divided into a training cohort (n = 598) and an internal validation cohort (n = 256). A further 222 patients from Sichuan Cancer Hospital & Institute were used to create an external validation cohort. Least absolute shrinkage and selection operator (LASSO) and Cox regression were used to identify independent risk factors for overall survival (OS). A nomogram (Nomogram-CA) was constructed and evaluated using the consistency index (C-index), calibration curves, time-dependent ROC (tdROC) and decision curve analysis (DCA). Kaplan-Meier survival curves were generated to show the difference in OS between groups. Age, CA stage, B symptoms and hemoglobin (Hb) level were all identified as independent risk factors for OS. Nomogram-CA was constructed based on multivariate analysis results. The DCA curves demonstrated that Nomogram-CA provided more net benefit to patients in the training, internal validation and external validation cohorts. Furthermore, analysis of the Kaplan-Meier survival curve revealed a significantly lower survival rate among patients identified as high-risk by Nomogram-CA when compared to those classified as low-risk (P < 0.05). Nomogram-CA constructed based on independent prognostic factors has better predictive ability compared to the traditional staging system, which can assist clinical doctors in evaluating patient prognosis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。